Personalised antiplatelet therapy during elective percutaneous coronary intervention in patients with chronic coronary syndrome: An international journal of cardiology expert consensus statement.
Oral P2Y12 inhibitors represent the mainstay therapy for the prevention of thrombotic complications in patients undergoing percutaneous coronary intervention (PCI) and coronary stent implantation. However, the onset of antiplatelet action of the oral P2Y12 inhibitors is affected by their need to be absorbed in the gast...